Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders

Journal of Neurology

Volumn 246, Issue 4, 1999, Pages 299-303

  Blaes, Franz ^a   Strittmatter, Mathias ^a   Merkelbach, Stefan ^a   Jost, Volker ^a   Klotz, Markus ^a   Schimrigk, Klaus ^a   Hamann, Gerhard F ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Intravenous immunoglobulins; Paraneoplastic neurological syndrome; Therapy

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BRAIN STEM; CEREBELLUM DEGENERATION; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; ENCEPHALITIS; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARANEOPLASTIC SYNDROME; POLYNEUROPATHY; PRIORITY JOURNAL; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PARANEOPLASTIC SYNDROMES;

EID: 0032943392     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050350     Document Type: Article

References (22)

1. 1. Blasczyk R, Westhoff U, Grosse-Wilde H (1993) Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341:789-790
2. 2. Cocconi G, Ceci G, Juvarra G, et al (1985) Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis. Cancer 56:2318-2320
3. 3. Counsell CE, McLeod M, Grant R (1994) Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 44: 1184-1185
4. 4. Cunningham J, Graus F, Anderson N, Posner JB (1986) Partial characterization of the Purkinje cell antigens in paraneoplastic cerebellar degeneration. Neurology 36:1163-1168
5. 5.Dalmau J, Posner JB (1996) Neurological paraneoplastic syndromes. Springer Semin Immunopathol 18: 85-95
6. 6. Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB (1991) Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 41:1757-1764
7. 7. Dalmau J, Furneaux HM, Cordon-Cardo C, Psoner JB (1992) The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 141:881-886
8. 8. Dalmau J, Graus F, Rosenblum MK, Posner JB (1992) Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy - a clinical study of 71 patients. Medicine (Baltimore) 71: 59-72
9. 9. Graus F, Vega F, Delattre JY, et al (1992) Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies. Neurology 42:536-540
10. 10. Grosse-Wilde H, Blasczyk A, Westhoff U (1992) Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens 39:74-77
11. 11. Hammack J, Kotanides H, Rosenblum MK, Posner JB (1992) Paraneoplastic cerebellar degeneration. II. Clinical and immunological findings in 21 patients with Hodgkin's disease. Neurology 42: 1938-1942
12. 12. Holzer G, Schimrigk K, Tönjes W (1988) Intrathekale Antikörpersynthese der IgG-Klasse gegen Masern-, Mumps- und Herpesviren und ihre Beziehung zu Multipler Sklerose und anderen neurologischen Erkrankungen. Aktuelle Neurol 15:97-101
13. 13. Klockgether T, Schroth G, Diener HC, Dichgans J (1990) Idiopathic cerebellar ataxia of late onset: Natural history and MRI morphology. J Neurol Neurosurg Psychiatry 53:297-305
14. 14. Modiano JF, Amran D, Lack G, Bradley K, Ball C, Domenico J, Gelfand EW (1997) Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopathol 83:77-85
15. 15. Moll JWB, Henzen-Logmans SC, Van der Meche FGA, Vecht CHJ (1993) Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 56:112
16. 16. Oh SJ, Dropcho EJ, Claussen GC (1997) Anti-Hu-associated paraneoplastic sensory neuronopathy responding to early aggressive immunotherapy: report of two cases and review of the literature. Muscle Nerve 20: 1576-1582
17. 17. Ronda N, Haury M, Nobrega A, Coutinho A, Kazatchkine MD (1994) Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin Immunol Immunopathol 70:124-128
18. 18. Stangel M, Hartung HP, Marx P, Gold R (1998) Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 153:203-214
19. 19. Stark E, Wurster U, Patzold U, Sailer M, Haas J (1995) Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 52: 814-818
20. 20. Tanaka K, Yamazaki M, Sato S, Toyoshima I, Yamamoto A, Miyatake T (1986) Antibodies to brain proteins in paraneoplastic cerebellar degeneration. Neurology 36:1169-1172
21. 21. Uchuya M, Graus F, Vega F, René F, Delattre JY (1996) Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal antibodies. J Neurol Neurosurg Psychiatry 60:388-392
22. 22. Yuste Ara JR, Beloqui Ruiz O, Artieda Gonzales-Granda J, Herrero Santos JI, De la Pena Fernandez A, Prieto Valtuena J (1996) Cyclosporin A in the treatment of Eaton-Lambert myasthenic syndrome. Ann Med Interne (Paris) 13:25-26